Cathie Wood’s ARK sells Tempus AI stock, buys Scribe Therapeutics

ARK Invest's largest September 23 trade was a $7.0M sale of 90,621 Tempus AI shares through ARKK, signaling a reduction in its exposure to the AI-healthcare company. ARK simultaneously added $4.0M of Scribe Therapeutics, $1.7M of Beam Therapeutics, and $0.9M of Veracyte through ARKG, extending recent accumulation in genomics and diagnostics names. The firm also trimmed $0.4M of Twist Bioscience and made a small $53,877 purchase of the 3iQ Solana Staking ETF.

Analysis

ARK activity is unlikely to be independently price-discovering in TEM, BEAM, VCYT, or TWST unless the orders represent an outsized share of daily volume; that liquidity context is missing. The more relevant transmission mechanism is positioning: ARK-linked names tend to carry concentrated retail and thematic ownership, so visible rebalancing can amplify short-term momentum and create temporary dislocations without changing enterprise value. TEM is particularly vulnerable to multiple compression if real yields continue higher because its valuation depends on distant AI-enabled healthcare monetization rather than near-term cash generation.

Within genomics, the apparent rotation favors companies with nearer commercial diagnostic revenue over capital-intensive platform stories, but ARK's transactions alone do not validate that fundamental distinction. VCYT could receive a modest technical bid if repeated buying absorbs available float, while TWST and BEAM remain more exposed to financing-cost sensitivity, trial-data volatility, and equity issuance risk over the next 6-18 months. The contrarian view is that a broad rate-driven selloff could create opportunity in BEAM only after a clinical catalyst or cash-runway confirmation; passive thematic accumulation is not sufficient evidence of a durable rerating.

Over the next several days, monitor TEM's relative performance versus the iShares Genomics Immunology and Healthcare ETF (IDNA) and ARKK rather than its absolute move. A sustained TEM underperformance after the disclosed selling would suggest broader holders are de-risking, whereas a quick reversal on normal volume would indicate the flow was readily absorbed. For 1-3 months, the key catalyst is whether Treasury yields stabilize: declining yields can mechanically re-expand long-duration healthcare multiples, overwhelming the informational content of these ETF trades.

Key Decisions for Investors

• Take no directional position solely from the disclosed ARK rebalancing; require daily-volume, ARK ownership, and borrow-utilization data before treating TEM or TWST selling as actionable supply.
• Establish a watchlist pair: long VCYT / short TWST only if VCYT outperforms TWST by at least 5% after the next earnings updates while VCYT maintains revenue guidance and TWST does not improve gross-margin or cash-burn guidance. Target 10-15% relative return over 3-6 months; exit if TWST raises guidance or VCYT cuts reimbursement-volume expectations.
• For existing TEM exposure, reduce beta or hedge with a short ARKK overlay while the 10-year yield remains in an uptrend. Re-add only following evidence of durable revenue-growth acceleration or a material improvement in adjusted EBITDA/FCF guidance; the near-term risk is valuation compression rather than a single ETF sale.
• Monitor BEAM for a catalyst-driven entry rather than chasing flow: consider a small long only after updated clinical data and confirmation of at least 24 months of cash runway. Falsification is safety-related trial delay, weaker editing efficacy, or financing that materially expands the share count.